Grants and Contributions:

Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).

Folia Biotech is a clinical-stage nanomedicine company working in the field of immunotherapy usingx000D
nanoparticles derived from papaya mosaic virus. En route toward clinical validation of their platformx000D
technology, they require further information on the blood circulation profile and biodistribution of their leadx000D
product.x000D
This proposal will be divided into two parts: 1) establishing a robust labeling method allowing tracking of theirx000D
nanoparticles in complex biological samples and 2) evaluating the circulation and biodistribution profiles ofx000D
their proprietary technology. Together, these objectives will allow Folia to acquire the methods necessary tox000D
further understand how their nanoparticle interact with biological environments. This project will offerx000D
technical knowledge and fundamental toxicology understanding. This will create value surrounding thex000D
proprietary technology, and foster the interest of pharmaceutical companies for collaborations.x000D
The academic lab involved in this project possesses accredited excellence in the labelling of nanoparticles andx000D
the evaluation of their circulation profiles. By advancing the development of a nanomedicine technology thatx000D
can be used for vaccination and immunotherapy, this project will create value for Canada, and contribute to thex000D
training of highly qualified personnel.